WOODBURY, NY, May 05, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its first quarter 2025 financial results on Thursday, May 8, 2025. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 8, 2025 to discuss its first quarter 2025 financial and operating results, as well as recent developments. Who: Joseph M. Harary, President & CEODate/Time: Thursday, May 8, 2025, 4:30 PM ETDial-in Information: 1-888-334-5785Conferen ...

Research Frontiers (REFR) Q4 2024 Earnings Call March 07, 2025 02:31 PM ET Company Participants Joseph Harary - CEO, President, General Counsel, Corporate Secretary & DirectorAlan Yakuboff - Partner & Wealth Manager Conference Call Participants None - Analyst Operator Good afternoon, and welcome to Research Frontiers Investor Conference Call to discuss the Fourth Quarter and Full Year twenty twenty four Results of Operations and Recent Developments. The company will be answering many of the questions that w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) of THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission File Number 000-14893 RESEARCH FRONTIERS INCORPORATED (Exact name of registrant as specified in its charter) DELAWARE 11-2103466 (State or other jurisdiction of incorporation or organization) 240 CROSSWAYS PARK DRIVE WOODBURY, NEW YORK 11797-2033 (Address of principal executive offices) (Z ...

WOODBURY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its fourth quarter and full-year 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.  •Who: Joseph M. Harary, President & CEO •Date/Time: Thursday, March 6, 2025, 4:30 PM ET •Dial-in Information:1-888-334-5785 •Replay: Available on Friday, March 7, 2025 for 90 days at https://smart ...

WOODBURY, NY, March 03, 2025 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its fourth quarter and full-year 2024 financial results on Thursday, March 6, 2025. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, March 6, 2025 to discuss its fourth quarter and full-year 2024 financial and operating results, as well as recent developments. Who: Joseph M. Harary, President & CEODate/Time: Thursday, March 6, 2025, 4:30 PM ETDial- ...

Event Overview - Research Frontiers Inc and Gauzy are showcasing SPD-SmartGlass technology at the 2024 CES show in Las Vegas, with Gauzy located at Booth 6516 in Automotive West Hall [1] - The event is expected to attract 150,000 attendees, who are invited to visit the Gauzy booth to see the latest developments and products using SPD-SmartGlass technology [1] Press Briefing and CEO Participation - A press briefing will be conducted by Research Frontiers and Gauzy on Thursday, with events for customers earlier in the week [2] - Eyal Peso, CEO of Gauzy, and Joe Harary, CEO of Research Frontiers Inc, will be present at Gauzy’s Booth 6516 on January 9 at 11am ET [2] Market and Industry Insights - The global smart glass market was estimated at $6 6 billion in 2023 and is expected to grow at a CAGR of 9 9% from 2023 to 2030 [3] - Smart glass technology is disrupting multi-billion-dollar industries such as aeronautics, automotive, and architecture [3] - Leading automotive manufacturer Ferrari has installed SPD Smart Glass in its top-selling SUV model [3] Applications and Benefits of Smart Glass - Smart glass allows passengers to control light in aircraft cabins through the touch of a button [3] - The technology is transforming built spaces from design to sustainability, advancing sustainability mandates for OEMs, property owners, and end-users [3] - Smart glass can change from transparent to opaque in milliseconds, enhancing the experience of light in various environments [4] Interactive Experience at CES - Attendees can meet the CEOs of Gauzy and Research Frontiers, who are behind the patents, production, and delivery of SPD Smart Glass [4] - The booth will showcase real-life applications of smart glass in smart buildings, homes, retrofit and new architectural construction, automotive, aircraft, and trains [4]

Research Frontiers Incorporated (NASDAQ:REFR) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Harary - President and CEO Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Third Quarter of 2024 Results of Operations and Recent Developments [Operator Instructions]. This conference is being recorded today. A replay of this conference call will be available starting later today in the Investors section o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DELAWARE 11-2103466 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) of THE SECURITIES AND EXCHANGE ACT OF 1934 For the quarter ended September 30, 2024 Commission File Number 000-14893 RESEARCH FRONTIERS INCORPORATED (Exact name of registrant as specified in its charter) 240 CROSSWAYS PARK DRIVE WOODBURY, NEW YORK 11797-2033 ...

WOODBURY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its third quarter 2024 financial results on Thursday, November 7, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 7, 2024 to discuss its third quarter 2024 financial and operating results, as well as recent developments. Who: Joseph M. Harary, President & CEODate/Time: Thursday, November 7, 2024, 4:30 PM ETDial-in Information: 1-888- ...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment. “We are excited to announce the ...